Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 139 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Toxicity;Chemical Clear all

Conditions: Smoking, Cigarette, Smoking, Tobacco, Nicotine Dependence, Exposure to Toxic Agent
Interventions: Low wattage E cigarette device, High wattage E cigarette device, Usual brand cigarette; Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 372 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer, Cardiac Toxicity, Cardiovascular Complications
Interventions: trastuzumab, doxorubicin hydrochloride, polymorphism analysis, laboratory biomarker analysis, questionnaire administration, assessment of therapy complications, magnetic resonance imaging; Biological · Drug · Genetic + 2 more
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 4
States / cities: Louisville, Kentucky • Nashville, Tennessee

Conditions: Cardiac Toxicity, Malignant Neoplasm, Breast Cancer
Interventions: Magnetic resonance imaging, Physical Activity, Healthy Living, Cardiopulmonary Exercise Testing (CPET), Questionnaire Administration; Procedure · Other · Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Richmond, Virginia

Conditions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Interventions: Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 14
States / cities: Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more

Conditions: Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Interventions: filgrastim, gene therapy, lomustine, procarbazine hydrochloride, vincristine sulfate, in vitro-treated peripheral blood stem cell transplantation; Procedure · Biological · Drug
Lead sponsor: Indiana University; Other
Eligibility: 5 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 2
States / cities: Indianapolis, Indiana • Boston, Massachusetts

Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
Interventions: amifostine trihydrate, cisplatin, etoposide, radiation therapy; Drug · Radiation
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Corneal Toxicity, Ototoxicity, Surgical Site Infection
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Liver Fibrosis, Steatohepatitis, Elevated Transaminases
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Cardiac Toxicity
Interventions: management of therapy complications; Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 105
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more

Conditions: Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions: dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, paclitaxel, trastuzumab, therapeutic conventional surgery, radiation therapy, tamoxifen citrate, laboratory biomarker analysis; Drug · Biological · Procedure + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Kidney Transplant; Complications, Toxicity, Drug Toxicity, Neurotoxicity
Interventions: Envarsus, IR Tacrolimus; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 60 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Interventions: Chinese herbs, cyclophosphamide, doxorubicin hydrochloride, adjuvant therapy; Dietary Supplement · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cardiac Toxicity, Early-stage Breast Cancer
Interventions: Lipitor 40mg Tablet; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 5 more

Conditions: HIV Infections
Interventions: Normosol-R, Nonoxynol-9, Gastrointestinal instrumentation; Drug · Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: glucarpidase; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1993
U.S. locations: 88
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 80 more

Conditions: Heart Failure, Coronary Artery Disease, Peripheral Artery Disease, Ischemia, Hypertension, Diabetes Mellitus, Cardiomyopathies, Cardiotoxicity
Interventions: Clinical Decision Aid, Standard Care; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Tobacco Use Disorder, Oral Nicotine Pouch Use, Smoking Behaviors, Harm Reduction, Toxic Effect of Tobacco and Nicotine, Carcinogenesis
Interventions: ZYN; Device
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 77 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes, Neutropenia
Interventions: amifostine trihydrate, cytarabine, mitoxantrone hydrochloride; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 4
States / cities: Chicago, Illinois • Kankakee, Illinois

Conditions: Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: amifostine trihydrate; Drug
Lead sponsor: Rush North Shore Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 1
States / cities: Skokie, Illinois

Conditions: Drug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer
Interventions: fluorouracil, gemcitabine hydrochloride, triacetyluridine; Drug
Lead sponsor: Wellstat Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 26
States / cities: Birmingham, Alabama • Burbank, California • Duarte, California + 22 more

Conditions: Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: pyridoxine hydrochloride, urea/lactic acid-based topical cream, placebo; Dietary Supplement · Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 231
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 148 more

Conditions: Anthracycline-induced Cardiotoxicity, Lymphoma, Chemotherapy, Cardiotoxicity
Interventions: Sotagliflozin, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity
Interventions: Donepezil; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 8 Years to 17 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Boston, Massachusetts • Winston-Salem, North Carolina

Conditions: Cardiotoxicity, Heart Failure, Breast Cancer, Anthracycline Induced Cardiomyopathy, Biomarkers, Echocardiography
Interventions: Not listed
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Stony Brook, New York

Search by objective public record fields.

Examination of Low Wattage and High Wattage E-Cigarettes

Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab

MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum

NATIENS: Optimal Management and Mechanisms of SJS/TEN

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer

A Comparison of Infection Rates Between Two Surgical Sites

Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy

SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients

Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides

Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate

PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study

Switching to Potential Reduced Exposure Products in Adult Smokers

Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML

Amifostine in Treating Patients With Cancer Who Have Neurological Changes Caused by Chemotherapy

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer

Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity

Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain

Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines